Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Astrazeneca Plc ADR (AZN)

Astrazeneca Plc ADR (AZN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
2 Unstoppable S&P 500 Dividend Stocks to Buy Before They Beat the Market Again

For over a decade, these two drugmakers consistently outperformed the benchmark index and could do it again.

ABBV : 192.94 (-0.26%)
AZN : 78.58 (+0.06%)
Study: Merck and Daiichi's Lung Cancer Treatment Shows Promise

Merck MRK announced that a phase study evaluating its Daiichi Sankyo-partnered HER3-directed DXd antibody drug conjugate (ADC), patritumab deruxtecan, for treating EGFR-mutated non-small cell lung cancer...

AZN : 78.58 (+0.06%)
PFE : 29.75 (-0.27%)
MRK : 118.64 (+0.30%)
LLY : 904.97 (-0.13%)
AZN Gets FDA Nod for Fasenra Label Expansion in Rare Disease

AstraZeneca AZN announced that the FDA has approved its marketed asthma drug, Fasenra (benralizumab) for a new indication. The regulatory body has now approved Fasenra for treating adult patients with...

REGN : 1,138.81 (-0.69%)
SNY : 57.47 (+0.98%)
AZN : 78.58 (+0.06%)
GSK : 42.43 (-0.31%)
Junior Biotech Utilizes AI To Shorten Drug Discovery Timelines, Ultimately Saving Lives

The urgent need for innovative technologies to accelerate the development of life-saving %Cancer therapies has never been more critical. With millions of lives and billions of dollars at stake, the potential...

MRK : 118.64 (+0.30%)
NVS : 115.97 (+0.23%)
KTRA : 0.1750 (-8.42%)
RKV.VN : 0.085 (-5.56%)
RHHBY : 39.6100 (+0.71%)
XBIT : 7.50 (+1.49%)
BMRN : 71.14 (+0.84%)
AZN : 78.58 (+0.06%)
SOPHiA GENETICS and AstraZeneca Collaborate to Further Expand Global Access to Liquid Biopsy Testing

/CNW/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native healthcare technology company and a global leader in data-driven medicine, today announced a new...

AZN : 78.58 (+0.06%)
SOPH : 4.37 (+9.80%)
AstraZeneca’s Stock Falls 5% As Cancer Drug Trial Disappoints

Shares of AstraZeneca (AZN) are down 5% after the British pharmaceutical company reported disappointing ...

AZN : 78.58 (+0.06%)
GSK's Respiratory Drug Nucala Meets Goal in COPD Study

GSK’s GSK phase III study evaluating its blockbuster drug Nucala (mepolizumab), an anti-IL5 biologic, for treating chronic obstructive pulmonary disease (COPD), met its primary endpoint.Data from the...

REGN : 1,138.81 (-0.69%)
SNY : 57.47 (+0.98%)
AZN : 78.58 (+0.06%)
GSK : 42.43 (-0.31%)
3 Market-Beating Stocks to Buy for Less Than $100

These stocks are all up more than 20% this year.

SBUX : 96.12 (-0.33%)
AZN : 78.58 (+0.06%)
CHWY : 30.90 (-3.65%)
CMG : 56.93 (-2.68%)
As Radiotherapy Redefines Cancer Care, Here's the Stock to Buy Near 52-Week Highs

A new generation of radiotherapies are redefining cancer care, offering the potential for a more powerful treatment with fewer side effects. It could become a mainstream therapy for the big "traditional"...

LLY : 904.97 (-0.13%)
AZN : 78.58 (+0.06%)
BMY : 49.74 (+0.51%)
NVS : 115.97 (+0.23%)
PFE : 29.75 (-0.27%)
Here's What AstraZeneca's CEO Has to Say About the Weight Loss Drugs Market

The winners of today might not compete in the lucrative new segment of tomorrow.

LLY : 904.97 (-0.13%)
AZN : 78.58 (+0.06%)

Barchart Exclusives

Stocks Soar Before the Open as Fed’s Big Rate Cut Boosts Sentiment, U.S. Economic Data and FedEx Earnings on Tap
September S&P 500 E-Mini futures (ESU24) are up +1.48%, and September Nasdaq 100 E-Mini futures (NQU24) are up +2.03% this morning on expectations the Federal Reserve’s half-percentage-point rate cut will steer the U.S. economy toward a “soft landing,” while investors awaited a new round of U.S. economic data and an earnings report from delivery services giant FedEx. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar